Plattform Life Sciences Interview with Dr Michael Thormann, CEO, Origenis
Together with the investor Kleiner Perkins, Origenis GmbH founded the company Neuron23 in the US in 2018. How did this come about and how does Origenis benefit from it? And is this type of spin-off a model that could be repeated?
Plattform Life Sciences: spoke to Origenis CEO Dr Michael Thormann about this.